Pari Mody counsels clients on legal and policy matters related to healthcare and US Food and Drug Administration regulated products, including pharmaceuticals, medical devices, foods, dietary supplements, and cosmetics.

Ms. Mody represents a wide range of clients, including manufacturers, healthcare systems, trade associations, and nonprofit research foundations She has experience navigating the legislative and regulatory processes, drafting legislative language, preparing comment letters, and developing and implementing legislative and regulatory strategies for individual clients and coalitions.

Ms. Mody has worked on significant healthcare legislation, including the 21st Century Cures Act, FDA Reauthorization Act of 2017, SUPPORT for Patients and Communities Act, and COVID-19 stimulus legislation.

Prior to joining the firm, Ms. Mody was an associate at another international law firm and worked as a researcher at the Johns Hopkins University and the University of Pennsylvania.


  • Pharmaceutical manufacturers in Congressional investigations and oversight hearings related to pricing, patents, and innovation.
  • Provider of in-home testing services in blocking a nearly 70 percent payment reduction for in-home EEG services through an integrated legislative and regulatory strategy, including direct advocacy and coalition building.
  • Medical device manufacturer in securing Medicare coverage for the client's device, following a multi-year, coordinated congressional and agency effort.
  • Manufacturer of FDA-regulated consumer products in challenges before the National Advertising Division of the Advertising Self-Regulatory Council.
  • Retailer of cosmetic and personal care products regarding product safety and managing Congressional inquiries.
  • Healthcare systems in securing enactment of legislative reforms that support coordination of care provided to medically complex children.
  • Two pro bono research and patient advocacy foundations in securing the introduction of bicameral, bipartisan legislation to authorize increased federal funding for research dedicated to a specific disease.


Best Lawyers
"Ones to Watch"—Health Care Law (2021–2023)
Excellence in Advocacy Awards
Finalist, Excellence in a Federal Issue Campaign (2017)


  • JD, University of Maryland Francis King Carey School of Law, magna cum laude, Order of the Coif
  • BA, Oberlin College, high honors
  • District of Columbia
  • Maryland
  • US District Court, District of Columbia

Email Disclaimer